Therefore, to overcome this issue, selectivity of the target was improved by engineering CAR T-cells with synthetic Notch (synNotch) receptors specific for EpCAM or B7-Homolog 3 (B7-H3), a member of the B7 family of immune checkpoint molecules, which is expressed on ROR1+ tumor cells but not on ROR1+ stromal cells, resulting in the regression of tumor cells without causing toxicity (Srivastava et al., 2019). The gene discussed is EPCAM; the disease is neoplasm.